Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Mok, Tony S., Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C., Kim, Hye R., Ramalingam, Suresh S., Shepherd, Frances A., He, Yong, Akamatsu, Hiroaki, Theelen, Willemijn S.M.E., Lee, Chee K., Sebastian, Martin, Templeton, Alison, Mann, Helen, Marotti, Marcelo, Ghiorghiu, Serban, Papadimitrakopoulou, Vassiliki A.·2017·New England Journal of Medicine
DOI 10.1056/nejmoa1612674

Cited by (1,003)

Items 401–500 of 1,003

  1. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
    Tereza Vaclová, Ursula Grazini, Lewis S. C. Ward, Daniel J. O’Neill, Aleksandra A. Markovets, Xiangning Huang, Juliann Chmielecki, Ryan James Hartmaier, Kenneth Stephen Thress, Paul D. Smith et al. · 2021 · Nature Communications
  2. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
    Tai‐Chung Lam, K.C. Tsang, Cheuk‐Wai Choi, Victor Ho-Fun Lee, Ka On Lam, Chi‐Leung Chiang, T.H. So, Wing‐Lok Chan, S.F. Nyaw, F. Lim et al. · 2021 · Lung Cancer
  3. First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
    Martina Lorenzi, Alessandra Ferro, Fabiana Letizia Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpía, Rita Chiari et al. · 2021 · The Oncologist
  4. Single‐cell RNA sequencing reveals cellular and molecular reprograming landscape of gliomas and lung cancer brain metastases
    Hefen Sun, Liangdong Li, I Weng Lao, Xuan Li, Baojin Xu, Yiqun Cao, Wei Jin · 2022 · Clinical and Translational Medicine
  5. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation
    Meredith K Bollinger, Amanda S Agnew, Gerard P. Mascara · 2017 · Journal of Oncology Pharmacy Practice
  6. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
    Lauretta Odogwu, Luckson Noe Mathieu, Kirsten B. Goldberg, Gideon Michael Blumenthal, Erin A. Larkins, Mallorie H. Fiero, Lisa Rodríguez, Karen E. Bijwaard, Eunice Y. Lee, Reena Philip et al. · 2017 · The Oncologist
  7. Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers
    Parth Malik, Tapan K. Mukherjee · 2018 · International Journal of Pharmaceutics
  8. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Qinghua Xu, Hui Liu, Shuyan Meng, Tao Jiang, Xuefei Li, Shi‐Xiong Liang, Shengxiang Ren, Caicun Zhou · 2019 · Journal of Cancer
  9. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
    Yuxin Mu, Xuezhi Hao, Puyuan Xing, Xingsheng Hu, Yan Wang, Teng Li, Jinyao Zhang, Ziyi Xu, Junling Li · 2020 · Journal of Cancer Research and Clinical Oncology
  10. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
    Toshinori Ando, Nadia Arang, Zhiyong Wang, Daniela Elena Costea, Xiaodong Feng, Yusuke Goto, Hiroki Izumi, Mara Gilardi, Kazuyo Ando, Jorge Silvio Gutkind · 2021 · Communications Biology
  11. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
    Fenneke Zwierenga, Bianca A. M. H. van Veggel, Lizza E.L. Hendriks, T. Jeroen N. Hiltermann, Birgitta I. Hiddinga, Lucie B.M. Hijmering-Kappelle, Arja ter Elst, Sayed M S Hashemi, Anne‐Marie C. Dingemans, Cor van der Leest et al. · 2022 · Lung Cancer
  12. Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib
    Julia K. Rotow, Jessica Lee, Russell William Madison, Geoffrey R. Oxnard, Pasi Antero Janne, Alexa Betzig Schrock · 2023 · Journal of Thoracic Oncology
  13. Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
    Mahesh Koirala, Mario DiPaola · 2024 · Biomedicines
  14. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer
    Bin Yan Wu, Xiaohua Gu, Qiang Zhang, Feng Xie · 2018 · The Oncologist
  15. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer
    Li Li, Yubo Wang, Lin Jiao, Caiyu Lin, Conghua Lu, Kejun Zhang, Chen Hu, Junyi Ye, Dadong Zhang, Haiyan Wu et al. · 2019 · Cancer Letters
  16. Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations
    Xuefei Li, Weijing Cai, Guohua Yang, Chunxia Su, Shengxiang Ren, Chao Zhao, Rongjun Hu, Xiaoxia Chen, Guanghui Gao, Zhiwei Guo et al. · 2017 · Journal of Thoracic Oncology
  17. A systematic review of targeted agents for non-small cell lung cancer
    Hannah Holm Vestergaard, Marcus R. Christensen, Ulrik Lassen · 2017 · Acta Oncologica
  18. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance
    Heinz Hammerlindl, Helmut Schaider · 2017 · Journal of Cell Communication and Signaling
  19. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib
    Yubo Wang, Li Li, Rui Han, Lin Jiao, Jie Zheng, Yong He · 2018 · Lung Cancer
  20. Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA 3 trial
    Hiroaki Akamatsu, Nobuyuki Katakami, Isamu Okamoto, Terufumi Kato, Young Hak Kim, Fumio Imamura, Masaharu Shinkai, Rachel A. Hodge, Hirohiko Uchida, Toyoaki Hida · 2018 · Cancer Science
  21. Molecular and Morphological Profiling of Lung Cancer: A Foundation for “Next-Generation” Pathologists and Oncologists
    Jumpei Kashima, Rui Kitadai, Yusuke Okuma · 2019 · Cancers
  22. The Evolving Landscape of Resistance to Osimertinib
    Adam Jacob Schoenfeld, Helena Alexandra Yu · 2019 · Journal of Thoracic Oncology
  23. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
    Kobayashi, Yoshihisa, Fujino, Toshio, Nishino, Masaya, Koga, Takamasa, Chiba, Masato, Sesumi, Yuichi, Ohara, Shuta, Shimoji, Masaki, Tomizawa, Kenji, Takemoto, Toshiki et al. · 2018 · Journal of Thoracic Oncology
  24. The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer
    Wen‐Zhao Zhong, Qing Hua Zhou, Yi-Long Lung Cancer Wu · 2017 · Oncotarget
  25. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
    Cheol‐Kyu Park, Hyun-Ju Cho, Yoo Duk Choi, In‐Jae Oh, Young‐Chul Kim · 2018 · Cancer Research and Treatment
  26. Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation
    Nikolaos Batis, Jill M. Brooks, Karl F.B. Payne, Neil Sharma, Paul Nankivell, Hisham Mohamed Mehanna · 2021 · Advanced Drug Delivery Reviews
  27. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI
    Tony S.K. Mok, Pasi Antero Janne, Makoto Nishio, Silvia Novello, Martin Reck, Conor Ernst Steuer, Yi-Long Wu, Ronan Fougeray, Pang‐Dian Fan, Jie Meng et al. · 2023 · Future Oncology
  28. NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
    Marc McGowan, Lilach Kleinberg, Ann Rita Halvorsen, Åslaug Helland, Odd Terje Brustugun · 2017 · Genes & Cancer
  29. Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
    Satoshi Yoda, Ibiayi Dagogo‐Jack, Aaron N. Hata · 2018 · Pharmacology & Therapeutics
  30. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
    Anna Truini, Jacqueline H. Starrett, Tyler Francis Stewart, Kumar Dilip Ashtekar, Zenta Walther, Anna Wurtz, David M. Lu, Jin H. Park, Michelle DeVeaux, Xiaoling Song et al. · 2019 · Clinical Cancer Research
  31. KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
    Mariantonia Nacchio, Roberta Sgariglia, Valerio Gristina, Pasquale Pisapia, Francesco Pepe, Caterina De Luca, Ilaria Migliatico, Eduardo Clery, Lorenza Greco, Elena Vigliar et al. · 2020 · Journal of Thoracic Disease
  32. Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress
    Shun Lü, Ignacio Casarini, Terufumi Kato, Manuel Cobo, Mustafa Özgüroğlu, Rachel A. Hodge, Toon van der Gronde, Matilde Saggese, Suresh S. Ramalingam · 2021 · Clinical Lung Cancer
  33. Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer
    Jae-Won Cho, Seyeon Park, Gamin Kim, Heonjong Han, Sunhye Shin, Sunhye Shin, Yong‐Soo Bae, Sung Yong Park, Sang‐Jun Ha, Insuk Lee et al. · 2021 · Nature Communications
  34. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
    Filippo de Marinis, Tae Min Kim, L. Bonanno, S. Cheng, S-W Kim, Marcello Tiseo, Quincy Siu-Chung Chu, C. Proto, Adrian Gerold Sacher, Y.-H. Luo et al. · 2025 · Annals of Oncology
  35. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
    Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu · 2018 · Critical Reviews in Oncology/Hematology
  36. Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
    Wenxiao Jiang, Guiqing Cai, Peter C. Hu, Yue Wang · 2018 · Acta Pharmaceutica Sinica B
  37. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
    Elena Helman, Minh Nguyen, Chris Karlovich, Darrin Despain, A. Karin Choquette, Alexander I. Spira, Helena Alexandra Yu, D. Ross Camidge, Thomas C. Harding, Richard Burnham Lanman et al. · 2018 · Clinical Lung Cancer
  38. Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
    Vanita Noronha, Akhil Rajendra, Amit Joshi, VijayMaruti Patil, Nandini N. Menon, Kumar Prabhash · 2019 · Cancer Research Statistics and Treatment
  39. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide
    Kailun He, Zhuo Zhang, Wenbing Wang, Xiaoliang Zheng, Xiaoju Wang, Xingxian Zhang · 2020 · Bioorganic & Medicinal Chemistry Letters
  40. First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
    Karim Amrane, Margaux Geier, R. Corre, H. Léna, Guillaume Leveiller, Florence Gadby, R. Lamy, Jean‐Louis Bizec, Eric Goarant, G. Robinet et al. · 2020 · Cancer Medicine
  41. An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib
    Wenxiao Jia, Hongbo Guo, Jing Wang, Xuquan Jing, Ji Li, Min Wang, Jinming Yu, Hui Zhu · 2020 · Radiotherapy and Oncology
  42. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM)
    Sehhoon Park, Richard Baldry, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Yu Jung Kim, Youngjoo Lee, Dong‐Wan Kim, Sang‐We Kim et al. · 2024 · Journal of Clinical Oncology
  43. Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead
    Danny Ulahannan, Jonathan Khalifa, Corinne Faivre Finn, Siow Ming Lee · 2017 · Annals of Oncology
  44. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
    Yen‐Ting Lin, Jin‐Shing Chen, Wei‐Yu Liao, Chao‐Chi Ho, Chia‐Lin Hsu, Ching‐Yao Yang, Kuan‐Yu Chen, Jih‐Hsiang Lee, Zhong‐Zhe Lin, Jin‐Yuan Shih et al. · 2018 · International Journal of Cancer
  45. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy
    Rahul Kumar, Harsh Goel, Raghu Solanki, Laxminarayan Rawat, Saba Tabasum, Pranay Tanwar, Soumitro Pal, Akash Sabarwal · 2024 · Medicine in Drug Discovery
  46. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
    Reyes Bernabé, Nicholas Hickson, Andrew J. Wallace, Fiona Helen Blackhall · 2017 · European Journal of Cancer
  47. Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring
    Chi‐Ju Kim, Juhee Park, Vijaya Sunkara, Tae-Hyeong Kim, Yongjin Lee, Kyusang Lee, Mi‐Hyun Kim, Yoon‐Kyoung Cho · 2018 · Lab on a Chip
  48. P5 eHealth: An Agenda for the Health Technologies of the Future
    Gabriella Pravettoni, Stefano Triberti · 2019 · Springer eBooks
  49. Assigning functionality to cysteines by base editing of cancer dependency genes
    Li, Haoxin, Ma, Tiantai, Remsberg, Jarrett R., Won, Sang Joon, DeMeester, Kristen E., Njomen, Evert, Ogasawara, Daisuke, Zhao, Kevin T., Huang, Tony P., Lu, Bingwen et al. · 2023 · Nature Chemical Biology
  50. Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
    Tristan Alexandra Barnes, Grainne Mary O'Kane, Mark David Vincent, Natasha B. Leighl · 2017 · Frontiers in Oncology
  51. Resistance to molecularly targeted therapy in non-small-cell lung cancer
    Tetsuhiko Asao, Fumiyuki Takahashi, Kazuhisa Takahashi · 2018 · Respiratory Investigation
  52. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
    Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman et al. · 2020 · Cancers
  53. Recent Trends of Lung Cancer in Korea
    Jae Guk Lee, Ho Cheol Kim, Chang‐Min Choi · 2021 · Tuberculosis & respiratory diseases
  54. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
    Yi Zhao, Bo Cheng, Zisheng Chen, Jianfu Li, Hengrui Liang, Ying Chen, Feng Zhu, Caichen Li, Ke Xu, Shan Xiong et al. · 2021 · Critical Reviews in Oncology/Hematology
  55. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations
    Hidetoshi Hayashi, Ernest Nadal, Jhanelle E. Gray, Andrea Ardizzoni, N. Caria, Tarun Puri, Christian Grohé · 2021 · Clinical Lung Cancer
  56. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
    Ishmael A. Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, Krishna Chaitanya Alluri, Narjust Florez, Shirish M. Gadgeel, Gregory A. Masters, Erin Lynn Schenk, Bryan James Schneider, Lecia Van Dam Sequist et al. · 2024 · Journal of Clinical Oncology
  57. Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA
    Helen J. Brown, Johan Vansteenkiste, Kazuhiko Nakagawa, Manuel Cobo, Thomas John, Craig Barker, Alexander Kohlmann, Alexander Todd, Matilde Saggese, Juliann Chmielecki et al. · 2019 · Journal of Thoracic Oncology
  58. Advances in Small-Cell Lung Cancer (SCLC) Translational Research
    Benjamin Jacob Drapkin, Charles M. Rudin · 2020 · Cold Spring Harbor Perspectives in Medicine
  59. Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
    Yuhan Zhang, Yaoshuai Zhang, Wenwen Niu, Xianming Ge, Fuhao Huang, Jinlong Pang, Xian Li, Yu Wang, Wei Gao, Fangtian Fan et al. · 2021 · Frontiers in Pharmacology
  60. Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
    Juan Bautista Blaquier, Andrés Felipe Cardona, Gonzalo Recondo · 2021 · Frontiers in Oncology
  61. Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
    Molly Siu Ching Li, Kevin K. S. Mok, Tony S.K. Mok · 2023 · Annals of Translational Medicine
  62. Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review
    Hiroki Izumi, Akira Yamasaki, Yasuto Ueda, Takashi Sumikawa, Hiroyuki Maeta, Shu Nakamoto, Eiji Shimizu · 2017 · Clinical Lung Cancer
  63. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
    Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Kun‐Chieh Chen, Chia-Hung Hsu, Kang‐Yi Su, Jeremy J.W. Chen, Huei‐Wen Chen, Sung‐Liang Yu, Tsung‐Ying Yang et al. · 2018 · Cancer Research and Treatment
  64. Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC
    Anna Buder, Maximilian Johannes Hochmair, Sophia Schwab, Tatjana Bundalo, Peter Schenk, Peter Errhalt, Romana E. Mikes, Gudrun Absenger, Kurt Patocka, Bernhard Baumgartner et al. · 2018 · Journal of Thoracic Oncology
  65. Imaging of Precision Therapy for Lung Cancer: Current State of the Art
    Hyesun Park, Lynette Marie Sholl, Hiroto Hatabu, Mark Magdi Awad, Mizuki Nishino · 2019 · Radiology
  66. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer
    Tadashi Manabe, Hiroyuki Yasuda, Hideki Terai, Harumi Kagiwada, Junko Hamamoto, Toshiki Ebisudani, Keigo Kobayashi, Keita Masuzawa, Shinnosuke Ikemura, Ichiro Kawada et al. · 2020 · Molecular Cancer Research
  67. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
    Noura J. Choudhury, Adam Jacob Schoenfeld, Jessica R. Flynn, Christina J. Falcon, Hira A. Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena Alexandra Yu et al. · 2021 · Clinical Cancer Research
  68. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
    Zixi Wang, Yurou Xing, Bingjie Li, Xiaoyu Li, Bin Liu, Yongsheng Wang · 2022 · Molecular Biomedicine
  69. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer
    Manmeet Singh Ahluwalia, Kevin Douglas Becker, Benjamin Philip Levy · 2018 · The Oncologist
  70. Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment
    Petra Schödel, Stephanie Theresa Jünger, Maike Wittersheim, Hans Christian Reinhardt, Nils Ole Schmidt, Roland Goldbrunner, Martin Andreas Proescholdt, Stefan Grau · 2020 · Cancer Medicine
  71. Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer
    Sanjay Popat · 2018 · New England Journal of Medicine
  72. HPV-related Sinonasal Carcinoma
    Rina Jiromaru, Hidetaka Yamamoto, Ryuji Yasumatsu, Takahiro Hongo, Yui Nozaki, Kazuki Hashimoto, Kenichi Taguchi, Muneyuki Masuda, Takashi Nakagawa, Yoshinao Oda · 2019 · The American Journal of Surgical Pathology
  73. Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
    Chia‐Yu Chu, Jennifer Nam Choi, Beth Eaby‐Sandy, Corey Jay Langer, Mario E. Lacouture · 2018 · The Oncologist
  74. Overview of precision oncology trials: challenges and opportunities
    Elena Fountzilas, Apostolia Maria Tsimberidou · 2018 · Expert Review of Clinical Pharmacology
  75. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
    Daniele Lavacchi, Francesca Mazzoni, Giuseppe Giaccone · 2019 · Drug Design Development and Therapy
  76. Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma
    James G. Connolly, Kay See Tan, Brooke Mastrogiacomo, Joseph Dycoco, Raul Caso, Gregory D. Jones, Patrick J. McCormick, Francisco Sánchez-Vega, Takeshi Irie, Joseph R. Scarpa et al. · 2021 · British Journal of Anaesthesia
  77. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
    Carmelo Laface, Felicia Maria Maselli, Anna Natalizia Santoro, Maria Laura Iaia, Francesca Ambrogio, Marigia Laterza, Chiara Guarini, Pierluigi De Santis, Martina Perrone, Palma Fedele · 2023 · Pharmaceutics
  78. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
    Saoirse Olivia Dolly, Dearbhaile Catherine Collins, Raghav Sundar, Sanjay Popat, Timothy A. Yap · 2017 · Drugs
  79. Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
    Manuel Caitano Maia, Paulo Gustavo Bergerot, Nazlı Dizman, Joann Hsu, Jeremy O. Jones, Richard Burnham Lanman, Kimberly C. Banks, Sumanta Kumar Pal · 2017 · Kidney Cancer
  80. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
    Shuyu Dan Li, Meng Ma, Hui Li, Aneta Waluszko, Tatyana Sidorenko, Eric E. Schadt, David Yu Zhang, Rong Chen, Fei Ye · 2017 · Genome Medicine
  81. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non–Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance
    Yuxiang Ma, Xin Xiao Zheng, Hongyun Zhao, Wenfeng Fang, Yang Zhang, Jieying Ge, Lu Wang, Weicong Wang, Ji Jiang, Shaokun Chuai et al. · 2018 · Journal of Thoracic Oncology
  82. Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?
    Sami Morin-Ben Abdallah, Annie Ngai Man Wong · 2018 · Current Oncology
  83. Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
    Satomi Watanabe, Hidetoshi Hayashi, Koji Haratani, Shigeki Shimizu, Junko Tanizaki, Kazuko Sakai, Hisato Kawakami, Kimio Yonesaka, Junji Tsurutani, Yosuke Togashi et al. · 2018 · Cancer Science
  84. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro
    Masaya Nishino, Kenichi Suda, Yoshihisa Kobayashi, Shuta Ohara, Toshio Fujino, T. Koga, Masato Chiba, Masaki Shimoji, Kenji Tomizawa, Toshiki Takemoto et al. · 2018 · Lung Cancer
  85. Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
    Xiaofei Wang, Ling Zhou, Jiani C. Yin, Xue Wu, Yang Washington Shao, Beili Gao · 2019 · Journal of Thoracic Oncology
  86. The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M
    Sam Butterworth, Darren A.E. Cross, M. Raymond V. Finlay, Richard A. Ward, Michael J. Waring · 2017 · MedChemComm
  87. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer
    Sally C. M. Lau, Ullas Batra, Tony S.K. Mok, Herbert Ho-Fung Loong · 2019 · Drugs
  88. Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands
    Janina Niggenaber, Leonie Heyden, Tobias Grabe, Matthias Philipp Müller, Jonas Lategahn, Daniel Rauh · 2020 · ACS Medicinal Chemistry Letters
  89. INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in MET -Amplified NSCLC and First-Line Osimertinib Resistance
    Egbert Frederik Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye Mun Tho, Xiuning Le, Julien Mazières, How Soon Hin, Masahiro Morise, Viola Weijia Zhu et al. · 2021 · Future Oncology
  90. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
    Judith N. Müller, Markus Falk, Jatin Talwar, Nicole Neemann, Erika Mariotti, Miriam Bertrand, Tobias Zacherle, Sotirios Lakis, Roopika Menon, Christian Gloeckner et al. · 2017 · Journal of Thoracic Oncology
  91. Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
    Robert Campbell, Geoffrey Chong, Eliza Anne Hawkes · 2018 · Journal of Clinical Medicine
  92. Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan
    Takashi Seto, Naoyuki Nogami, Nobuyuki Yamamoto, Shinji Atagi, Naoki Tashiro, Yoko Yoshimura, Yutaka Yabuki, Hideo Saka · 2018 · Oncology and Therapy
  93. ASTRIS: A Global Real-World Study of Osimertinib in >3000 Patients with EGFR T790M Positive Non-Small-Cell Lung Cancer
    Filippo de Marinis, Yi-Long Lung Cancer Wu, Gilberto de Castro, Gee‐Chen Chang, Yuh-Min Chen, Byoung Chul Cho, H. Freitas, Liyan Jiang, Sang-We Kim, Claudio Marcelo Martin et al. · 2019 · Future Oncology
  94. Genetic profiling of cancer with circulating tumor DNA analysis
    Ling Lu, Junqin Bi, Liming Bao · 2018 · Journal of genetics and genomics/Journal of Genetics and Genomics
  95. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer
    Thomas John, Hiroaki Akamatsu, Angelo Delmonte, Wu‐Chou Su, Jong Seok Lee, Gee‐Chen Chang, Xiangning Huang, Suzanne C. Jenkins, Yi-Long Lung Cancer Wu · 2018 · Lung Cancer
  96. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
    Hiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara‐Konishi, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto et al. · 2021 · Lung Cancer
  97. The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
    Steven W. Criscione, Matthew J. Martin, Derek B. Oien, Aparna Gorthi, Ricardo J. Miragaia, Jingwen Zhang, Huawei Chen, Daniel L. Karl, Kerrin Mendler, Aleksandra A. Markovets et al. · 2022 · npj Precision Oncology
  98. Scientific Advances in Thoracic Oncology 2016
    Ross Andrew Soo, Emily C.A. Stone, K. Michael Cummings, James R. Jett, John K. Field, Harry J.M. Groen, James L. Mulshine, Yasushi Yatabe, Lukas Bubendorf, Sanja Đačić et al. · 2017 · Journal of Thoracic Oncology
  99. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers
    Karthick Vishwanathan, Paul Alfred Dickinson, Khanh Bui, Philippe Alexandre Cassier, Alastair Greystoke, Eleanor A. Lisbon, Víctor Moreno, Karen So, Karen Thomas, Doris K. Weilert et al. · 2017 · The Journal of Clinical Pharmacology
  100. Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
    Hongge Liang, Xiaoyan Liu, Mengzhao Wang · 2018 · OncoTargets and Therapy